AGIOS PHARMACEUTICALS, INC. business relationships
Companies named in AGIOS PHARMACEUTICALS, INC.’s 10-K filed 2026-02-12, and public companies whose annual reports name AGIOS PHARMACEUTICALS, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.9 / 10
- AI naming
- 22 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in AGIOS PHARMACEUTICALS, INC.’s annual report 2
“• the amount and timing of future milestone and royalty payments potentially payable to Alnylam Pharmaceuticals, Inc. pursuant to the license agreement entered into in July 2023;” SEC filing
“...$363.4 million during the year ended December 31, 2024 was primarily due to the proceeds from the Upfront Payment from Royalty Pharma and the Vorasidenib Milestone Payment from Servier, partially offset by higher purchases of marketable securities than proceeds from maturities and sales of marketab...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.